AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$30.29
arrow_upward
+1.44%(+0.43) 1D
$30.00
arrow_downward
-0.96% (-0.29)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMLX...
Open
$29.66
High
$31.57
Low
$28.86
Mkt. cap
3.89B
Avg. vol.
1.38M
Volume
1.62M
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.45
Beta
-0.09
Shares outstanding
128.56M
No. of employees
136
Open
$29.66
High
$31.57
Low
$28.86
Mkt. cap
3.89B
Avg. vol.
1.38M
Volume
1.62M
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.45
Beta
-0.09
Shares outstanding
128.56M
No. of employees
136
News stories
From web sources and news partners
GuruFocus
·
1 day ago
Co-CEO Justin Klee Sells 100,000 Shares of Amylyx Pharmaceuticals (AMLX)
Quantisnow
·
1 day ago
Amylyx Pharmaceuticals (AMLX) CEO Klee sold 100,000 shares for $2.98M at an average $29.84 under a 10b5-1 plan
Investing.com
·
3 days ago
Amylyx at Stifel 2026 healthcare conference: avexitide nears launch
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc
CEO-
Employees136
Founded2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteamylyx.com